Hemophilia A – Landscape & Forecast – Disease Landscape & Forecast (G7)

Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides superior outcomes; for non-inhibitor patients, the drug’s less-frequent dosing and subcutaneous administration offer significant convenience. The next decade promises to be pivotal for hemophilia A therapy (both with and without inhibitors), driven by the adoption of Sanofi / SOBI’s Altuviiio / Altuvoct, groundbreaking gene therapy (Biomarin’s Roctavian), and the emergence of innovative nonfactor agents such as Sanofi’s fitusiran, Pfizer’s Hympavzi (marstacimab), and Novo Nordisk’s Alhemo (concizumab) and Mim8. Supported by insights from thought leaders, we assess the impact of new drug therapies on the treatment of hemophilia A. This report does not cover the perioperative management of hemophilia A, hemophilia A carriers, or patients with acquired hemophilia A.

• What is the current treatment landscape for hemophilia A? What are physicians’ experience and satisfaction with current key therapies?
• How will the introduction of Altuviiio / Altuvoct and the emergence of other nonfactor therapies affect the Hemlibra-dominated hemophilia A market?
• How will the management of patients with or without inhibitors evolve as new nonfactor treatments beyond Hemlibra launch?
• How will nonfactor treatment options impact the multitude of FVIII therapies competing for patient share?
• What are the prescribing considerations dictating physician preferences for hemophilia A with and without inhibitor treatments, and how do they vary by country / region?

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.